{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-008336","form_type":"8-K","ticker":"PBSV","cik":"0001304161","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2022-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.139071+00:00","generated_at":"2026-06-25T01:53:42.862276+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Pharma-Bio Serv Q2 FY2022 revenue $5.0M, net income $0.2M; stable YoY","bullets":["Revenue for Q2 ended April 30, 2022 was ~$5.0M, up ~$0.1M from prior-year quarter.","Net income for Q2 was ~$0.2M, reflecting no significant change YoY.","Six-month revenue ~$10.0M, net income ~$0.5M, both essentially flat YoY.","CEO cites steady execution and focus on client services amid global uncertainties."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-008336","json":"https://secwatch.observer/filing/0001654954-22-008336.json","markdown":"https://secwatch.observer/filing/0001654954-22-008336.md","text":"https://secwatch.observer/filing/0001654954-22-008336.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1304161/000165495422008336/0001654954-22-008336-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1304161/000165495422008336/pbsv_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T01:53:42.862276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}